Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2016
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 27 Jul 2016 Status changed from recruiting to completed.
- 03 May 2014 Interim results presented at the 66th Annual Meeting of the American Academy of Neurology.
- 06 Dec 2013 Planned end date changed from 1 Dec 2012 to 1 Jan 2016 as reported by ClinicalTrials.gov.